Responses
Regular and young investigator award abstracts
Clinical trials in progress
413 GEN-009, a personalized neoantigen vaccine, elicits robust immune responses in individuals with advanced or metastatic solid tumors
Compose a Response to This Article
Other responses
No responses have been published for this article.
